Clinical trial · no report yet · Phase 2
NCT04592237
Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer
- NCT04592237 ↗
- Active not recruiting
- M.D. Anderson Cancer Center
- 5 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| X threads | 5 |
The trial
ClinicalTrials.gov- Official title
- Randomized Phase II Study of Platinum-Taxane-Cetrelimab Induction Followed by Niraparib Plus or Minus Cetrelimab Maintenance in Men With Aggressive Variant Prostate Cancers
- Phase
- Phase 2
- Status
- Active not recruiting
- Conditions
- Aggressive Variant Prostate Carcinoma; Castration-Resistant Prostate Carcinoma; Metastatic Prostate Carcinoma; Metastatic Prostate Neuroendocrine Carcinoma; Metastatic Prostate Small Cell Carcinoma; Stage IV Prostate Cancer AJCC v8
- Interventions
- Cabazitaxel; Carboplatin; Cetrelimab; Niraparib
- Arms
- Group I (niraparib) · Experimental
- Group II (cetrelimab, niraparib) · Experimental
- Enrollment
- 120 (estimated)
- Primary outcomes
- Progression-free survival
- Sponsor
- M.D. Anderson Cancer Center with Janssen Pharmaceutica
- Start
- Dec 29, 2020
- Primary completion
- Dec 31, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT04592237 · updated Sep 9, 2026